司美格鲁肽与利尿剂在肥胖相关射血分数保留心衰中的应用:STEP-HFpEF和STEP-HFpEF-DM试验汇总分析
该汇总分析纳入STEP-HFpEF和STEP-HFpEF-DM试验中1145例肥胖相关HFpEF患者,随机接受每周司美格鲁肽2.4mg或安慰剂治疗52周。结果显示,司美格鲁肽在各利尿剂使用亚组中均改善心衰症状和体力限制,且基线使用袢利尿剂者获益更显著;同时司美格鲁肽减少袢利尿剂使用及剂量。
要点
- 司美格鲁肽在各利尿剂亚组中一致改善体重和心衰症状。
- 基线使用袢利尿剂者KCCQ-CSS改善更显著。
- 司美格鲁肽减少袢利尿剂剂量及使用概率。
核心结论
- 在肥胖相关HFpEF患者中,司美格鲁肽在各利尿剂使用亚组中改善心衰相关症状和体力限制,基线使用袢利尿剂者获益更明显。
- 司美格鲁肽减重和改善运动功能的效果在各利尿剂类别中一致。
- 司美格鲁肽减少52周内袢利尿剂的使用和剂量。
研究设计与样本
- STEP-HFpEF和STEP-HFpEF-DM试验的预设汇总分析,纳入1145例HFpEF且BMI≥30 kg/m2患者。
- 随机接受每周司美格鲁肽2.4 mg或安慰剂治疗52周。
- 按基线利尿剂使用情况分组:无利尿剂(n=220)、仅非袢利尿剂(n=223)、袢利尿剂<40(n=219)、40(n=309)、>40(n=174)mg/日呋塞米等效剂量。
临床怎么用
- 对于肥胖相关HFpEF患者,司美格鲁肽可考虑用于改善心衰症状和体力限制,尤其基线使用袢利尿剂者。
- 使用司美格鲁肽期间可预期袢利尿剂剂量减少,需监测并调整利尿剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: In the STEP-HFpEF trial programme, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose. METHODS: In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM trials (n = 1145), which randomized participants with HFpEF and body mass index ≥ 30 kg/m2 to once weekly semaglutide 2.4 mg or placebo for 52 weeks, we examined whether efficacy and safety endpoints differed by baseline diuretic use, as well as the effect of semaglutide on loop diuretic use and dose changes over the 52-week treatment period. RESULTS: At baseline, across no diuretic (n = 220), non-loop diuretic only (n = 223), and loop diuretic [<40 (n = 219), 40 (n = 309), and >40 (n = 174) mg/day furosemide equivalents] groups, there was progressively higher prevalence of hypertension and atrial fibrillation; and greater severity of obesity and heart failure. Over 52 weeks of treatment, semaglutide had a consistent beneficial effect on change in body weight across diuretic use categories (adjusted mean difference vs. placebo ranged from -8.8% [95% confidence interval (CI) -10.3, -6.3] to -6.9% [95% CI -9.1, -4.7] from no diuretics to the highest loop diuretic dose category; interaction P = .39). Kansas City Cardiomyopathy Questionnaire clinical summary score improvement was greater in patients on loop diuretics compared to those not on loop diuretics (adjusted mean difference vs. placebo: +9.3 [6.5; 12.1] vs. +4.7 points [1.3, 8.2]; P = .042). Semaglutide had consistent beneficial effects on all secondary efficacy endpoints (including 6 min walk distance) across diuretic subgroups (interaction P = .24-.92). Safety also favoured semaglutide vs. placebo across the diuretic subgroups. From baseline to 52 weeks, loop diuretic dose decreased by 17% in the semaglutide group vs. a 2.4% increase in the placebo group (P < .0001). Semaglutide (vs. placebo) was more likely to result in loop diuretic dose reduction (odds ratio [OR] 2.67 [95% CI 1.70, 4.18]) and less likely dose increase (OR 0.35 [95% CI 0.23, 0.53]; P < .001 for both) from baseline to 52 weeks. CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide improved heart failure-related symptoms and physical limitations across diuretic use subgroups, with more pronounced benefits among patients receiving loop diuretics at baseline. Reductions in weight and improvements in exercise function with semaglutide vs. placebo were consistent in all diuretic use categories. Semaglutide also led to a reduction in loop diuretic use and dose between baseline and 52 weeks. CLINICAL TRIAL REGISTRATION: NCT04788511 and NCT04916470.
引用
- Shah, Sharma, Borlaug, et al. Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials. Eur Heart J. 2024. PMID: 38739118. doi:10.1093/eurheartj/ehae322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。